Pfizer Inc
Healthy Returns: FDA may add its strongest safety warning to Covid vaccines. Here’s what to know
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Food and Drug Administration may add its strongest safety warning to Covid shots – marking another major shift in vaccine oversight. It could also expand a […]
Read More
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand […]
Read More
The Fed meeting, pressure on Oracle, Target’s fashion-forward renovation and more in Morning Squawk
Television stations broadcast Jerome Powell, chairman of the US Federal Reserve, speaking after a Federal Open Market Committee (FOMC) meeting on the floor of the New York Stock Exchange in New York, US, on Wednesday, Oct. 29, 2025. Michael Nagle | Bloomberg | Getty Images This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions […]
Read More
Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company’s pill
Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021. John Thys | Reuters Pfizer on Tuesday said it has struck an […]
Read More
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
Drug pricing has emerged as a key topic to watch for pharmaceutical companies and investors in 2025. As President Donald Trump pushes for lower medicine prices for Americans, the sector is facing additional pricing pressure from a Biden-era law called the Inflation Reduction Act. The IRA, voted into law in 2022, allows the Centers for […]
Read More
Novo Nordisk’s leadership strategy tested as shareholders signal frustration ahead of vote on board revamp
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images A leadership shakeup at what was once Europe’s […]
Read More
Stocks making the biggest moves midday: Walt Disney, Sweetgreen, Cisco, Planet Fitness and more
Check out the companies making headlines in midday trading: Planet Fitness — The gym chain jumped about 4% after it issued guidance for the fiscal years 2026 through 2028. Planet Fitness expects new club unit growth to range between 6% and 7% in that time, while adjusted EBITA expands in the “mid-teens percent” compounded annually. […]
Read More
Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional data
A view shows a Novo Nordisk sign outside its office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, on July 14, 2025. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. All […]
Read More
Novo Nordisk walked away from a $10 billion biotech deal — and investors aren’t sure if that’s smart or scary
Novo Nordisk has a lot on its plate — and it may not all be healthy. The pharmaceutical giant pulled out of its bidding war against rival Pfizer for clinical-stage biotech Metsera when the U.S. juggernaut matched its latest offer. Metsera accepted Pfizer’s $10 billion deal — significantly more than what Pfizer had initially offered […]
Read More
Metsera accepts Pfizer’s $10 billion bid in ongoing M&A battle
Smith Collection | Archive Photos | Getty Images Obesity drug developer Metsera said on Friday that it had accepted Pfizer‘s $10 billion acquisition offer, in what could spell the end of a bidding war between the New York-based pharma giant and rival Novo Nordisk that erupted over the last week. Pfizer had appeared to have […]
Read More